ADMA Biologics Reports Record 2025 Financial Results, Strong 2026-2029 Guidance, and Smooth CFO Transition

summarizeSummary

ADMA Biologics reported record full-year 2025 financial results, including 20% revenue growth and 40% Adjusted EBITDA growth, alongside strong multi-year guidance and a planned CFO transition.

check_boxKey Events

• Record Full Year 2025 Financial Results

  ADMA Biologics reported total revenue of $510.2 million for FY 2025, representing 20% year-over-year growth. Adjusted Net Income grew 35% to $160.8 million, and Adjusted EBITDA increased 40% to $231.0 million.

• Strong Multi-Year Financial Guidance

  The company provided optimistic guidance, expecting FY 2026 total revenue to exceed $635 million and Adjusted EBITDA to exceed $360 million. Long-term targets include over $1.1 billion in annual revenue and greater than $700 million in Adjusted EBITDA by 2029.

• Planned CFO Transition Announced

  Brad Tade is retiring as Chief Financial Officer and Treasurer, effective February 25, 2026, and will transition to a consulting role. Terry Kohler, previously Executive Financial Advisor, has been promoted to succeed him, effective February 26, 2026.

• Operational and Pipeline Progress

  The company highlighted strong ASCENIV demand, strategic plasma network actions to improve supply and capital efficiency, full commercial operation of yield-enhanced production, and advancement of its SG-001 pipeline program towards an FDA pre-IND meeting in 2026.

auto_awesomeAnalysis

ADMA Biologics has delivered a highly positive update, showcasing robust financial performance for 2025 with significant revenue and Adjusted EBITDA growth. The company's forward guidance for 2026 through 2029 projects continued strong growth, reinforcing investor confidence in its long-term trajectory. The announced CFO transition appears well-managed, with the outgoing CFO moving to a consulting role and an experienced internal candidate stepping into the position, ensuring leadership continuity during a period of anticipated margin expansion and cash flow generation. This filing provides comprehensive financial details and strategic updates that build upon previous preliminary disclosures, offering a clear and optimistic outlook for the company's operational and financial future.